Day: March 12, 2024

HOUSTON, March 12, 2024 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“VAALCO” or the “Company”) today announced that the Company is scheduled to participate in the 36th Annual Roth Conference to be held in Dana Point, California from March 17-19, 2024.  Ronald Bain, Chief Financial Officer and Edward Cozens, Vice President of Commercial and Strategic Planning will participate in the Conference and host one-on-one meetings with investors during the event. An updated investor presentation will be posted on the Company’s web site www.vaalco.com in the “Investor Relations” section on the “Presentations” page prior to the event. About VAALCO VAALCO, founded in 1985 and incorporated under the laws of Delaware, is a Houston, U.S.-based, independent energy company with production, development and exploration assets in...

Coop Pank’s financial results in February 2024:In February, number of the bank’s clients increased by 2,100 and number of active clients increased by 1,500. By the end of the month number of clients reached 187,100 and number of active clients reached 82,600. Over the year, customer base has grown by 23%. Volume of the bank’s customer deposits decreased by 26 million euros, reaching 1.72 billion euros by the end of month. Deposits of corporate customers decreased by 14 million euros and deposits of private customers increased by 1 million euros. The volume of deposits attracted from international platforms decreased by 13 million euros. Over the year, volume of bank deposits has grown by 14%. The bank’s loan portfolio increased by 7 million euros and reached 1.52 billion euros by the end of February. Business loans...

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions. Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering. The gross proceeds to...